When OCD Isn’t Just OCD
I was reading a post this week from an account called PANDA. Promoting Autism Neurodiversity Awareness.
Interesting acronym, given where this is going.
The piece was about why autistic girls without intellectual disability are uniquely vulnerable to OCD. It walked through masking as chronic cognitive load. It explained intrusive thoughts that feel alien and distressing to the person having them. It described the loop that engages with a thought and accidentally teaches the brain to treat it as a real threat. It cited the research showing OCD occurs in 17-37% of autistic youth, five to six times the rate in neurotypical peers.
All of that is accurate, and it is useful.
But it stops at the edge of something bigger.
Because what looks like an autistic teenager burning out and developing OCD at thirteen, fifteen, seventeen, isn't always what it looks like.
And when you treat it as though it is, some of these young people don't get better.
What the piece gets right
Masking is not a preference. It is years of full-time cognitive load running in the background, monitoring facial expressions, anticipating social rules, pre-empting mistakes. It uses the same executive function capacity that everything else in your child's life also needs. It doesn't switch off.
By the time a bright autistic teenager has been masking for a decade, the system is depleted. The meltdowns at home, the rigidity, the sudden flatness. These are not character changes. They are the pressure valve of a nervous system that has been running on override for years.
And the piece is right that when executive function finally gives out, intrusive thoughts can lock in. The brain's gear-shifting mechanism was already compromised. Now it has even less capacity to move on from a thought once it has taken hold.
What the piece doesn’t say
What the piece doesn't say is that years of masking don't just exhaust cognitive resources. They reshape biology.
Chronic activation of the stress response system, the HPA axis, depletes the body in specific ways. Zinc and magnesium are often depleted. The tryptophan pathway, the one that should be making serotonin and melatonin, gets pulled down a different road.
Under inflammatory conditions, tryptophan is preferentially shunted into the kynurenine pathway rather than towards serotonin production. This produces neuroactive metabolites including quinolinic acid, which overstimulates the NMDA glutamate receptor and drives excitotoxicity.1
Less serotonin. More neuroactive metabolites that irritate the brain.
Many of these young people also carry genetic variants that compound this. MTHFR and other methylation variants. SOD2 polymorphisms affecting oxidative defence. Add in gut barrier dysfunction and mineral depletion, and the biology is depleted long before anyone starts talking about burnout.
When the crash arrives
A virus at the end of term. Another round of COVID. A strep throat nobody swabbed. Glandular fever.
And within weeks, something changes.
The intrusive thoughts are new. The food starts getting complicated, foods they used to eat are suddenly off the list. Their world shrinks. They can't leave the house, or they can't be in certain rooms, or they can't stop washing their hands. The fears don't match anything that is actually happening. A bright child who could read anything three months ago now can't get through a page.
The line we hear again and again from parents is, "this isn't them."
This is what gets called autistic burnout with comorbid OCD. Sometimes that is correct. In many of the children we see, it is PANS.
The case nobody's making
Paediatric Acute-onset Neuropsychiatric Syndrome (PANS), and its streptococcal subset PANDAS, exist in the research literature, but almost no child in the UK is given this diagnosis. When the label is used at all, it is for a seven-year-old with an overnight change after strep. Sudden OCD, tics, handwriting difficulties, urinary frequency, food restriction.
That is not what most of these children look like.
The PANS Research Consortium criteria have no upper age limit.2 The research on adolescents has been building for years. There is a documented case of a woman whose PANDAS onset began at nineteen, following a confirmed episode of mononucleosis and group A streptococcal infection, with abrupt severe anxiety, OCD, and food restriction.3 Cox and colleagues documented antineuronal antibodies in a cohort of young people presenting with tics and OCD.4
The overnight-onset picture is far less clean than people assume. Of the first 47 patients treated at the Stanford PANS Clinic, only 40% had acute onset. 31% developed symptoms over three days to eight weeks. 29% developed them over more than eight weeks.5
This is a big part of why these children get missed. When an infection hits a child whose body has been under strain for years, the symptoms don't always appear overnight. They build over weeks, sometimes months. By the time anyone is paying attention, the conversation has already turned to burnout, or anxiety, or autism, and stayed there.
What the infection does is bring to the surface a body that has been struggling to keep up for years.
It gets missed in boys too. The cultural image is the burnt-out high-achieving girl, and the boys with the same biology don't fit the picture.
Why standard therapy stalls
ERP (Exposure and Response Prevention) is the evidence-based treatment for OCD. It works, often brilliantly, when the OCD is driven by a brain that has learned to treat intrusive thoughts as real threats.
It does not resolve inflammation in the brain.
Antibodies that attack the basal ganglia, the brain region central to OCD, are about five times more common in people with OCD than in people without.6 In one earlier study, nearly 20% of adults with OCD tested positive. In the controls, it was 4%.7
This has been in the psychiatric literature for more than a decade.
When immune activation is part of the driver, talking therapy can only do so much. The biology has to be looked at as well.
What we see when we look properly
When you test properly, not the routine bloods that come back "normal", certain patterns come up over and over.
A chronic viral burden, usually EBV, HHV-6 or CMV, at titres the routine GP panel does not measure. Strep markers that stay elevated without a recent sore throat. Mineral depletion and very low plasma amino acids. Altered tryptophan metabolism with raised 5-HIAA. Alongside these, gut inflammatory signatures, dysregulated cortisol, and mitochondrial stress markers appear frequently.
Once the immune system, the minerals, the infections, the adrenals, and the gut are all being worked on alongside the psychological work, the OCD starts to move. That is the bit that surprises the families who have been in ERP for years.
What families can do
Find someone who can assess both sides. A psychologist who only does CBT or ERP cannot investigate a neuroimmune flare. A GP who only looks at routine bloods will miss it. You need someone looking at cellular immune markers, viral titres, strep markers, mineral status, and mitochondrial function.
Look at the infection history in detail. Strep (even without a classic sore throat), EBV, CMV, HHV-6, Lyme, Mycoplasma, COVID. The infection they "just got over" is often the one that tipped the system.
Support the HPA axis. Magnesium, B vitamins, adaptogens where appropriate, proper rest without pushing through.
Rebuild minerals. Zinc, magnesium, selenium, copper in balance, and enough iron where it is low.
Address inflammation. Remove dietary triggers. Sort the gut.
Keep the psychological work going. The piece from PANDA still applies. Don't engage with intrusive thoughts. Don't reassure. Don't argue with them. Do this while treating the biology, not instead of.
Don't accept "just anxiety" or "just burnout" as a final answer when what you are living with at home doesn't fit that description.
For these children, the label of autistic burnout is often what keeps them stuck, and the driver goes unaddressed. When the biology is identified and supported, the OCD starts to improve.
IMPORTANT
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult with medical doctors or qualified functional medicine practitioners before introducing any new supplement, test, or intervention.
If this has raised questions about your child, we'd love to help you find some answers.
REFERENCES
1. Lim CK, Essa MM, de Paula Martins R, et al. Altered kynurenine pathway metabolism in autism: Implication for immune-induced glutamatergic activity. Autism Research. 2016;9(6):621-631. doi:10.1002/aur.1565.
2. Chang K, Frankovich J, Cooperstock M, et al. Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference. Journal of Child and Adolescent Psychopharmacology. 2015;25(1):3-13. doi:10.1089/cap.2014.0084.
3. Kulumani Mahadevan LS, Murphy M, Selenica M, Latimer E, Harris BT. Clinicopathologic Characteristics of PANDAS in a Young Adult: A Case Report. Developmental Neuroscience. 2023;45(6):335-341. doi:10.1159/000534061.
4. Cox CJ, Zuccolo AJ, Edwards EV, et al. Antineuronal antibodies in a heterogeneous group of youth and young adults with tics and obsessive-compulsive disorder. Journal of Child and Adolescent Psychopharmacology. 2015;25(1):76-85. doi:10.1089/cap.2014.0048.
5. Frankovich J, Thienemann M, Pearlstein J, Crable A, Brown K, Chang K. Multidisciplinary Clinic Dedicated to Treating Youth with Pediatric Acute-Onset Neuropsychiatric Syndrome: Presenting Characteristics of the First 47 Consecutive Patients. Journal of Child and Adolescent Psychopharmacology. 2015;25(1):38-47. doi:10.1089/cap.2014.0081.
6. Pearlman DM, Vora HS, Marquis BG, Najjar S, Dudley LA. Anti-basal ganglia antibodies in primary obsessive-compulsive disorder: systematic review and meta-analysis. British Journal of Psychiatry. 2014;205(1):8-16. doi:10.1192/bjp.bp.113.137018.
7. Nicholson TRJ, Ferdinando S, Krishnaiah RB, et al. Prevalence of anti-basal ganglia antibodies in adult obsessive-compulsive disorder: cross-sectional study. British Journal of Psychiatry. 2012;200(5):381-386. doi:10.1192/bjp.bp.111.092007.